Compare Amphastar Pharmaceuticals Inc (AMPH) vs Upstart Holdings Inc (UPST) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Upstart Holdings (UPST) trades at $32.74, down 1.47% on the day, with a bullish technical signal and neutral oscillators. The company reported a return to profitability in 2025 with $53.60M net income on $1.02B revenue, though recent quarterly earnings missed expectations. Analyst consensus is mixed with a $42.00 price target, and the stock is positioned between key support at $32 and resistance at $34.

The outlook hinges on execution of AI lending growth and funding stability, with upside potential from product expansion, but risks include margin pressure, debt levels, and macroeconomic sensitivity. The stock offers a speculative growth opportunity amid improving fundamentals but requires careful risk management.